In research that should be essential reading for anyone involved in attempts to reduce US drug prices, it has been found that more than 40% of the money spent by consumers on pharmaceuticals goes to intermediaries.
Pharmacy benefit managers (PBMs), insurers, pharmacies and wholesalers are taking their share of the 41%, according to a study published on the website Health Affairs on Tuesday.
"Efforts to control drug costs should focus on the rents enjoyed by all players in the distribution system"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze